Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.35 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.35 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.35 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048133 | 0.85 | MRGPRX4 (0.39) | MRGPRX4ALDH1A1TAAR1PLAAT3PLAAT5 | |
| SCHEMBL5725361 | 0.85 | PLAAT3 (0.39) | MRGPRX4ALDH1A1HPGDTAAR1PLAAT3 | |
| SCHEMBL5727377 | 0.85 | TAAR1 (0.39) | MRGPRX4ALDH1A1HPGDTAAR1PLAAT3 | |
| SCHEMBL5726264 | 0.84 | SLC2A1 (0.43) | MRGPRX4ALDH1A1HPGDTAAR1PLAAT3 | |
| SCHEMBL5727230 | 0.84 | TAS2R14 (0.39) | MRGPRX4ALDH1A1HPGDTAAR1PLAAT3 | |
| SCHEMBL5047954 | 0.82 | PLAAT3 (0.42) | ALDH1A1HPGDTAAR1PLAAT3PLAAT5 | |
| SCHEMBL5046689 | 0.82 | PLAAT3 (0.41) | MRGPRX4ALDH1A1HPGDTAAR1PLAAT3 | |
| SCHEMBL5726138 | 0.82 | GRM5 (0.42) | GRM5MRGPRX4ALDH1A1HPGDTAAR1 | |
| SCHEMBL5043616 | 0.82 | PLAAT3 (0.41) | ALDH1A1HPGDTAAR1PLAAT3PLAAT5 | |
| SCHEMBL5725353 | 0.81 | MRGPRX4 (0.40) | MRGPRX4ALDH1A1HPGDTAAR1PLAAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PFIZER INC. | 2005-09-15 | — | — | US | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PTGER2, PTGES2, PTGFR | GRM5 592/4885MRGPRX4 141/4885ALDH1A1 3293/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | GRM5 715/4885MRGPRX4 199/4885ALDH1A1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.